Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.

Shrestha S, Zhang C, Jerde CR, Nie Q, Li H, Offer SM, Diasio RB.

Clin Pharmacol Ther. 2018 Jan 12. doi: 10.1002/cpt.1020. [Epub ahead of print]

PMID:
29327356
2.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A.

Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Review.

PMID:
29208398
3.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.

Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M.

Clin Pharmacol Ther. 2018 Feb;103(2):210-216. doi: 10.1002/cpt.911. Epub 2017 Nov 20.

PMID:
29152729
4.

Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity.

Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, Lee AM, Wu R, Jerde CR, Wang Z, Kubica PA, Offer SM, Diasio RB.

Clin Pharmacol Ther. 2017 Oct;102(4):662-670. doi: 10.1002/cpt.685. Epub 2017 May 26.

PMID:
28295243
5.

Drug metabolism and pancreatic cancer.

Flores JP, Diasio RB, Saif MW.

Ann Gastroenterol. 2017;30(1):54-61. doi: 10.20524/aog.2016.0074. Epub 2016 Jul 21. Review.

6.

Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter.

Wu R, Nie Q, Tapper EE, Jerde CR, Dunlap GS, Shrestha S, Elraiyah TA, Offer SM, Diasio RB.

Cancer Res. 2016 Nov 1;76(21):6362-6373. Epub 2016 Aug 30.

7.

Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.

Elraiyah T, Jerde CR, Shrestha S, Wu R, Nie Q, Giama NH, Sarangi V, Roberts LR, Offer SM, Diasio RB.

Clin Pharmacol Ther. 2017 Mar;101(3):382-390. doi: 10.1002/cpt.531. Epub 2016 Nov 26.

8.

Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.

Saif MW, Smith MH, Maloney A, Diasio RB.

Ann Gastroenterol. 2016 Oct-Dec;29(4):551-556. Epub 2016 Jun 10.

9.

Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers.

Nardi EA, Wolfson JA, Rosen ST, Diasio RB, Gerson SL, Parker BA, Alvarnas JC, Levine HA, Fong Y, Weisenburger DD, Fitzgerald CL, Egan M, Stranford S, Carlson RW, Benz EJ Jr.

J Natl Compr Canc Netw. 2016 Jul;14(7):837-47.

PMID:
27407124
10.
11.

Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.

Saif MW, Diasio RB.

Cancer Chemother Pharmacol. 2016 Jul;78(1):151-6. doi: 10.1007/s00280-016-3063-1. Epub 2016 Jun 8.

PMID:
27278667
12.

A phosphotyrosine switch regulates organic cation transporters.

Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N.

Nat Commun. 2016 Mar 16;7:10880. doi: 10.1038/ncomms10880.

13.

Biomarkers of Fluorouracil Toxicity: Insight From the PETACC-8 Trial.

Offer SM, Diasio RB.

JAMA Oncol. 2016 Jan 21. doi: 10.1001/jamaoncol.2015.5463. [Epub ahead of print] No abstract available.

PMID:
26797288
14.

Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient.

Saif MW, Wasif K, Butler-Bowen H, Miller K, Diasio RB.

Therap Adv Gastroenterol. 2016 Jan;9(1):121-7. doi: 10.1177/1756283X15604115. No abstract available.

15.

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB.

Pharmacogenet Genomics. 2016 Mar;26(3):133-7. doi: 10.1097/FPC.0000000000000197.

16.

Is It Finally Time for a Personalized Medicine Approach for Fluorouracil-Based Therapies?

Offer SM, Diasio RB.

J Clin Oncol. 2016 Jan 20;34(3):205-7. doi: 10.1200/JCO.2015.64.2546. Epub 2015 Dec 7. No abstract available.

PMID:
26644533
17.

Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.

Jang JS, Lee A, Li J, Liyanage H, Yang Y, Guo L, Asmann YW, Li PW, Erickson-Johnson M, Sakai Y, Sun Z, Jeon HS, Hwang H, Bungum AO, Edell ES, Simon VA, Kopp KJ, Eckloff B, Oliveira AM, Wieben E, Aubry MC, Yi E, Wigle D, Diasio RB, Yang P, Jen J.

Sci Rep. 2015 May 18;5:9755. doi: 10.1038/srep09755.

18.

Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.

Amstutz U, Offer SM, Sistonen J, Joerger M, Diasio RB, Largiadèr CR.

Clin Cancer Res. 2015 May 1;21(9):2038-44. doi: 10.1158/1078-0432.CCR-14-2817. Epub 2015 Feb 5.

19.

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB.

J Natl Cancer Inst. 2014 Nov 7;106(12). pii: dju298. doi: 10.1093/jnci/dju298. Print 2014 Dec.

20.

Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).

Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB.

Clin Cancer Res. 2014 Jun 15;20(12):3319-27. doi: 10.1158/1078-0432.CCR-14-0069. Epub 2014 Apr 11.

21.

Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.

Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB.

Cancer Res. 2014 May 1;74(9):2545-54. doi: 10.1158/0008-5472.CAN-13-2482. Epub 2014 Mar 19.

22.

Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility.

Lee AM, Diasio RB.

J Clin Oncol. 2014 Apr 1;32(10):989-90. doi: 10.1200/JCO.2013.53.4479. Epub 2014 Mar 3. No abstract available.

PMID:
24590640
23.

microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites.

Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB.

Mol Cancer Ther. 2014 Mar;13(3):742-51. doi: 10.1158/1535-7163.MCT-13-0878. Epub 2014 Jan 8.

24.

A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.

Saif MW, Lee AM, Offer SM, McConnell K, Relias V, Diasio RB.

Mayo Clin Proc. 2014 Jan;89(1):131-136. doi: 10.1016/j.mayocp.2013.09.008.

25.

HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.

Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA.

Cancer. 2014 Feb 1;120(3):415-24. doi: 10.1002/cncr.28435. Epub 2013 Oct 21.

26.

Response to "A case of 5-FU-related severe toxicity associated with the P.Y186C DPYD variant".

Offer SM, Diasio RB.

Clin Pharmacol Ther. 2014 Feb;95(2):137. doi: 10.1038/clpt.2013.207. Epub 2013 Oct 9. No abstract available.

27.

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M.

Clin Pharmacol Ther. 2013 Dec;94(6):640-5. doi: 10.1038/clpt.2013.172. Epub 2013 Aug 29.

28.

Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy.

Witzig TE, Hu G, Offer SM, Wellik LE, Han JJ, Stenson MJ, Dogan A, Diasio RB, Gupta M.

Leukemia. 2014 Jan;28(1):147-54. doi: 10.1038/leu.2013.251. Epub 2013 Aug 27.

29.

A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity.

Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB.

Clin Pharmacol Ther. 2013 Jul;94(1):158-66. doi: 10.1038/clpt.2013.69. Epub 2013 Apr 3.

30.

Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.

Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB.

Cancer Res. 2013 Mar 15;73(6):1958-68. doi: 10.1158/0008-5472.CAN-12-3858. Epub 2013 Jan 17.

31.

The clinical case for proton beam therapy.

Foote RL, Stafford SL, Petersen IA, Pulido JS, Clarke MJ, Schild SE, Garces YI, Olivier KR, Miller RC, Haddock MG, Yan E, Laack NN, Arndt CA, Buskirk SJ, Miller VL, Brent CR, Kruse JJ, Ezzell GA, Herman MG, Gunderson LL, Erlichman C, Diasio RB.

Radiat Oncol. 2012 Oct 22;7:174. doi: 10.1186/1748-717X-7-174. Review.

32.

A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC).

Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MA.

Lung Cancer. 2013 Jan;79(1):27-32. doi: 10.1016/j.lungcan.2012.09.013. Epub 2012 Oct 16.

33.

Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.

Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA.

J Clin Oncol. 2012 Nov 10;30(32):3932-8. doi: 10.1200/JCO.2012.43.1890. Epub 2012 Sep 17.

34.

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.

Siddiq A, Couch FJ, Chen GK, Lindström S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Rhie SK, Ambrosone CB, Aittomäki K, Amiano P, Apicella C; Australian Breast Cancer Tissue Bank Investigators, Baglietto L, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Brauch H, Brinton L, Bui QM, Buring JE, Buys SS, Campa D, Carpenter JE, Chasman DI, Chang-Claude J, Chen C, Clavel-Chapelon F, Cox A, Cross SS, Czene K, Deming SL, Diasio RB, Diver WR, Dunning AM, Durcan L, Ekici AB, Fasching PA; Familial Breast Cancer Study, Feigelson HS, Fejerman L, Figueroa JD, Fletcher O, Flesch-Janys D, Gaudet MM; GENICA Consortium, Gerty SM, Rodriguez-Gil JL, Giles GG, van Gils CH, Godwin AK, Graham N, Greco D, Hall P, Hankinson SE, Hartmann A, Hein R, Heinz J, Hoover RN, Hopper JL, Hu JJ, Huntsman S, Ingles SA, Irwanto A, Isaacs C, Jacobs KB, John EM, Justenhoven C, Kaaks R, Kolonel LN, Coetzee GA, Lathrop M, Le Marchand L, Lee AM, Lee IM, Lesnick T, Lichtner P, Liu J, Lund E, Makalic E, Martin NG, McLean CA, Meijers-Heijboer H, Meindl A, Miron P, Monroe KR, Montgomery GW, Müller-Myhsok B, Nickels S, Nyante SJ, Olswold C, Overvad K, Palli D, Park DJ, Palmer JR, Pathak H, Peto J, Pharoah P, Rahman N, Rivadeneira F, Schmidt DF, Schmutzler RK, Slager S, Southey MC, Stevens KN, Sinn HP, Press MF, Ross E, Riboli E, Ridker PM, Schumacher FR, Severi G, Dos Santos Silva I, Stone J, Sund M, Tapper WJ, Thun MJ, Travis RC, Turnbull C, Uitterlinden AG, Waisfisz Q, Wang X, Wang Z, Weaver J, Schulz-Wendtland R, Wilkens LR, Van Den Berg D, Zheng W, Ziegler RG, Ziv E, Nevanlinna H, Easton DF, Hunter DJ, Henderson BE, Chanock SJ, Garcia-Closas M, Kraft P, Haiman CA, Vachon CM.

Hum Mol Genet. 2012 Dec 15;21(24):5373-84. doi: 10.1093/hmg/dds381. Epub 2012 Sep 13.

35.

Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma.

Greenberg AJ, Lee AM, Serie DJ, McDonnell SK, Cerhan JR, Liebow M, Larson DR, Colby CL, Norman AD, Kyle RA, Kumar S, Rajkumar SV, Diasio RB, Slager SL, Vachon CM.

Leukemia. 2013 Feb;27(2):515-6. doi: 10.1038/leu.2012.232. Epub 2012 Aug 16. No abstract available.

36.

Identification of a novel percent mammographic density locus at 12q24.

Stevens KN, Lindstrom S, Scott CG, Thompson D, Sellers TA, Wang X, Wang A, Atkinson E, Rider DN, Eckel-Passow JE, Varghese JS, Audley T, Brown J, Leyland J, Luben RN, Warren RM, Loos RJ, Wareham NJ, Li J, Hall P, Liu J, Eriksson L, Czene K, Olson JE, Pankratz VS, Fredericksen Z, Diasio RB, Lee AM, Heit JA, DeAndrade M, Goode EL, Vierkant RA, Cunningham JM, Armasu SM, Weinshilboum R, Fridley BL, Batzler A, Ingle JN, Boyd NF, Paterson AD, Rommens J, Martin LJ, Hopper JL, Southey MC, Stone J, Apicella C, Kraft P, Hankinson SE, Hazra A, Hunter DJ, Easton DF, Couch FJ, Tamimi RM, Vachon CM.

Hum Mol Genet. 2012 Jul 15;21(14):3299-305. doi: 10.1093/hmg/dds158. Epub 2012 Apr 24.

37.

Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.

Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA.

Clin Cancer Res. 2012 Jan 15;18(2):546-54. doi: 10.1158/1078-0432.CCR-11-2272.

38.

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.

Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Blot WJ, Brauch H, Buring JE, Carey LA, Carpenter JE, Chang-Claude J, Chanock SJ, Chasman DI, Clarke CL, Cox A, Cross SS, Deming SL, Diasio RB, Dimopoulos AM, Driver WR, Dünnebier T, Durcan L, Eccles D, Edlund CK, Ekici AB, Fasching PA, Feigelson HS, Flesch-Janys D, Fostira F, Försti A, Fountzilas G, Gerty SM; Gene Environment Interaction and Breast Cancer in Germany (GENICA) Consortium, Giles GG, Godwin AK, Goodfellow P, Graham N, Greco D, Hamann U, Hankinson SE, Hartmann A, Hein R, Heinz J, Holbrook A, Hoover RN, Hu JJ, Hunter DJ, Ingles SA, Irwanto A, Ivanovich J, John EM, Johnson N, Jukkola-Vuorinen A, Kaaks R, Ko YD, Kolonel LN, Konstantopoulou I, Kosma VM, Kulkarni S, Lambrechts D, Lee AM, Marchand LL, Lesnick T, Liu J, Lindstrom S, Mannermaa A, Margolin S, Martin NG, Miron P, Montgomery GW, Nevanlinna H, Nickels S, Nyante S, Olswold C, Palmer J, Pathak H, Pectasides D, Perou CM, Peto J, Pharoah PD, Pooler LC, Press MF, Pylkäs K, Rebbeck TR, Rodriguez-Gil JL, Rosenberg L, Ross E, Rüdiger T, Silva Idos S, Sawyer E, Schmidt MK, Schulz-Wendtland R, Schumacher F, Severi G, Sheng X, Signorello LB, Sinn HP, Stevens KN, Southey MC, Tapper WJ, Tomlinson I, Hogervorst FB, Wauters E, Weaver J, Wildiers H, Winqvist R, Van Den Berg D, Wan P, Xia LY, Yannoukakos D, Zheng W, Ziegler RG, Siddiq A, Slager SL, Stram DO, Easton D, Kraft P, Henderson BE, Couch FJ.

Nat Genet. 2011 Oct 30;43(12):1210-4. doi: 10.1038/ng.985.

39.

Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma.

Yoon HH, Lewis MA, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope FA.

J Clin Oncol. 2011 Dec 1;29(34):4561-7. doi: 10.1200/JCO.2011.37.1260. Epub 2011 Oct 11.

40.

Common breast cancer susceptibility loci are associated with triple-negative breast cancer.

Stevens KN, Vachon CM, Lee AM, Slager S, Lesnick T, Olswold C, Fasching PA, Miron P, Eccles D, Carpenter JE, Godwin AK, Ambrosone C, Winqvist R, Brauch H; GENICA consortium, Schmidt MK, Cox A, Cross SS, Sawyer E, Hartmann A, Beckmann MW, Schulz-Wendtland R, Ekici AB, Tapper WJ, Gerty SM, Durcan L, Graham N, Hein R, Nickels S, Flesch-Janys D, Heinz J, Sinn HP, Konstantopoulou I, Fostira F, Pectasides D, Dimopoulos AM, Fountzilas G, Clarke CL, Balleine R, Olson JE, Fredericksen Z, Diasio RB, Pathak H, Ross E, Weaver J, Rüdiger T, Försti A, Dünnebier T, Ademuyiwa F, Kulkarni S, Pylkäs K, Jukkola-Vuorinen A, Ko YD, Van Limbergen E, Janssen H, Peto J, Fletcher O, Giles GG, Baglietto L, Verhoef S, Tomlinson I, Kosma VM, Beesley J, Greco D, Blomqvist C, Irwanto A, Liu J, Blows FM, Dawson SJ, Margolin S, Mannermaa A, Martin NG, Montgomery GW, Lambrechts D, dos Santos Silva I, Severi G, Hamann U, Pharoah P, Easton DF, Chang-Claude J, Yannoukakos D, Nevanlinna H, Wang X, Couch FJ.

Cancer Res. 2011 Oct 1;71(19):6240-9. doi: 10.1158/0008-5472.CAN-11-1266. Epub 2011 Aug 15.

41.

The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection.

Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrope FA, Diasio RB.

Mayo Clin Proc. 2010 Dec;85(12):1080-9. doi: 10.4065/mcp.2010.0421.

42.

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.

Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D; EMBRACE, Peock S, Cook M, Oliver C, Frost D, Eccles D, Evans DG, Eeles R, Izatt L, Chu C, Douglas F, Paterson J, Stoppa-Lyonnet D, Houdayer C, Mazoyer S, Giraud S, Lasset C, Remenieras A, Caron O, Hardouin A, Berthet P; GEMO Study Collaborators, Hogervorst FB, Rookus MA, Jager A, van den Ouweland A, Hoogerbrugge N, van der Luijt RB, Meijers-Heijboer H, Gómez García EB; HEBON, Devilee P, Vreeswijk MP, Lubinski J, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Górski B, Cybulski C, Spurdle AB, Holland H; kConFab, Goldgar DE, John EM, Hopper JL, Southey M, Buys SS, Daly MB, Terry MB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Preisler-Adams S, Arnold N, Niederacher D, Sutter C, Domchek SM, Nathanson KL, Rebbeck T, Blum JL, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Blank SV, Friedman E, Kaufman B, Laitman Y, Milgrom R, Andrulis IL, Glendon G, Ozcelik H, Kirchhoff T, Vijai J, Gaudet MM, Altshuler D, Guiducci C; SWE-BRCA, Loman N, Harbst K, Rantala J, Ehrencrona H, Gerdes AM, Thomassen M, Sunde L, Peterlongo P, Manoukian S, Bonanni B, Viel A, Radice P, Caldes T, de la Hoya M, Singer CF, Fink-Retter A, Greene MH, Mai PL, Loud JT, Guidugli L, Lindor NM, Hansen TV, Nielsen FC, Blanco I, Lazaro C, Garber J, Ramus SJ, Gayther SA, Phelan C, Narod S, Szabo CI; MOD SQUAD, Benitez J, Osorio A, Nevanlinna H, Heikkinen T, Caligo MA, Beattie MS, Hamann U, Godwin AK, Montagna M, Casella C, Neuhausen SL, Karlan BY, Tung N, Toland AE, Weitzel J, Olopade O, Simard J, Soucy P, Rubinstein WS, Arason A, Rennert G, Martin NG, Montgomery GW, Chang-Claude J, Flesch-Janys D, Brauch H; GENICA, Severi G, Baglietto L, Cox A, Cross SS, Miron P, Gerty SM, Tapper W, Yannoukakos D, Fountzilas G, Fasching PA, Beckmann MW, Dos Santos Silva I, Peto J, Lambrechts D, Paridaens R, Rüdiger T, Försti A, Winqvist R, Pylkäs K, Diasio RB, Lee AM, Eckel-Passow J, Vachon C, Blows F, Driver K, Dunning A, Pharoah PP, Offit K, Pankratz VS, Hakonarson H, Chenevix-Trench G, Easton DF, Couch FJ.

Nat Genet. 2010 Oct;42(10):885-92. doi: 10.1038/ng.669. Epub 2010 Sep 19.

43.

A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors.

Saif MW, Sellers S, Diasio RB, Douillard JY.

Anticancer Drugs. 2010 Aug;21(7):716-23. doi: 10.1097/CAD.0b013e32833cb658.

44.

ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?

Lee AM, Diasio RB.

Clin Cancer Res. 2010 Jul 1;16(13):3319-21. doi: 10.1158/1078-0432.CCR-10-1059. Epub 2010 Jun 22.

45.

A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.

Fakih MG, Fetterly G, Egorin MJ, Muindi JR, Espinoza-Delgado I, Zwiebel JA, Litwin A, Holleran JL, Wang K, Diasio RB.

Clin Cancer Res. 2010 Jul 15;16(14):3786-94. doi: 10.1158/1078-0432.CCR-10-0547. Epub 2010 May 12.

46.

(13)C-5-FU breath test current status and future directions: a comprehensive review.

Ezzeldin HH, Acosta EP, Mattison LK, Fourie J, Modak A, Diasio RB.

J Breath Res. 2009 Dec;3(4):047002. doi: 10.1088/1752-7155/3/4/047002. Epub 2009 Nov 27.

PMID:
21386199
47.

Histone deacetylase inhibitors: current status and overview of recent clinical trials.

Ma X, Ezzeldin HH, Diasio RB.

Drugs. 2009 Oct 1;69(14):1911-34. doi: 10.2165/11315680-000000000-00000. Review.

PMID:
19747008
48.

Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.

Saif MW, Hashmi S, Bell D, Diasio RB.

Expert Opin Drug Saf. 2009 Sep;8(5):507-14. doi: 10.1517/14740330903173217.

PMID:
19663627
49.

DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.

Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB.

Pak J Med Sci. 2007;23(6):832-839.

50.

Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation?

Saif MW, Juneja V, Black G, Thronton J, Johnson MR, Diasio RB.

Support Cancer Ther. 2007 Sep 1;4(4):211-8. doi: 10.3816/SCT.2007.n.017.

PMID:
18632519

Supplemental Content

Loading ...
Support Center